source
- Elevar Therapeutics receives FDA approval for Lyrfigtu as second-line treatment for bile duct cancerThe U.S. Food and Drug Administration has approved Elevar Therapeutics' drug Lyrfigtu as a second‑line option for patients with bile duct cancer who meet specific criteria. Bile duct cancer is dia…
- AI doomsday warnings may curb health-tech innovation, Epic cautionsRecent commentary warns that sensational AI doomsday predictions could slow the pace of health‑technology innovation. Epic, the large electronic health‑record company that provides AI tools to hos…